Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) has issued an announcement.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has announced an update on its continuous risk assessment report concerning its financial service agreement with Tianjin Pharmaceutical Group Finance Co., Ltd. (TPGF), a related finance company. This update is in compliance with the Shanghai Stock Exchange’s requirements for listed companies engaged in transactions with related finance companies. The company has entered into a three-year financial service agreement with TPGF, which includes various financial services such as settlement, deposit, and credit business services. The risk assessment ensures that TPGF meets the necessary operating qualifications and business conditions, thereby maintaining transparency and regulatory compliance, which is crucial for stakeholders.
More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhongxin Pharmaceutical Group Corporation Limited, is incorporated in the People’s Republic of China. The company operates within the pharmaceutical industry and is involved in providing a range of pharmaceutical products and services. It has a market focus on integrating financial services with its pharmaceutical operations through its subsidiary, Tianjin Pharmaceutical Group Finance Co., Ltd.
YTD Price Performance: 4.14%
Technical Sentiment Signal: Sell
Current Market Cap: €3.67B
For an in-depth examination of 2TZ stock, go to TipRanks’ Stock Analysis page.